Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Mark Marcellus who wrote (2500)	4/11/2000 8:10:00 PM
From: Hank	Read Replies (1) \| Respond to of 5582

I'm not surprised to hear of VPHM's failure. However, what I found really interesting was this part: "Another company, New Jersey drugmaker Warner-Lambert Co. (NYSE:WLA - news), said last December one of its experimental medicines significantly reduced symptoms of the common cold in Phase II trials. Warner-Lambert's intranasal drug, code-named AG7088 and developed by the company's Agouron unit, is designed to inhibit a protease enzyme that cold viruses need to replicate. Larger trials are now under way." Looks like a legitimate nasal drug for colds is on the way and you can bet there won't be any phony delays in completing the clinical trials or failure by the FDA to review the data. GUMM is toast if WLA gets approval, if not sooner.